Skip to content
Catalyst

PapersPMID:19809023

Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial.

JAMA2009The record ↗

  1. Finding, very limited evidencelowersLate-onset sepsis incidence (neonatal)

What moved

1 findingHow to read these marks →
  • “Incidence of late-onset sepsis was significantly lower in the BLF and BLF plus LGG groups (9/153 [5.9%] and 7/151 [4.6%], respectively) than in the control group receiving placebo (29/168 [17.3%]) (risk ratio, 0.34; 95% confidence interval, 0.17-0.70; P = .002 for BLF vs control and risk ratio, 0.27; 95% confidence interval, 0.12-0.60; P < .001 for BLF plus LGG vs control).”
    Study
    RCT
    Effect
    0.34 risk ratio, 95% CI 0.17 to 0.7
    Dose studied
    100 mg/day orally from birth until day 30 of life (day 45 for neonates <1000 g at birth)
    Population
    Very low birth weight (<1500 g) neonates in 11 Italian tertiary neonatal intensive care units

Study record

Design
randomised controlled trial
Species
human
Population
VLBW (<1500 g) infants in 11 Italian tertiary neonatal intensive care units; oral bovine lactoferrin alone, bovine lactoferrin plus Lactobacillus rhamnosus GG, or placebo from birth until day 30 of life (day 45 for <1000 g); abstract only
Participants
472
Comparator
placebo
Duration
not reported
Endpoints measured
3